- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
Enhance Solid Tumor Profile Plus™ with optional immunohistochemistry testing for PD-L1, FOLR1, CLDN18, and MET, adding clinically relevant protein expression insights to comprehensive DNA and RNA molecular profiling.
The IHC Add-On for Solid Tumor Profile Plus™ expands comprehensive molecular profiling with immunohistochemistry testing for PD-L1, FOLR1, CLDN18, and MET. This additional layer of analysis helps identify clinically relevant biomarkers that may support treatment selection, including eligibility assessment for immunotherapies and targeted therapies in appropriate patients. Combined with the broad DNA and RNA capabilities of Solid Tumor Profile Plus™, this add-on provides a more complete view of tumor biology and helps physicians make more informed precision oncology decisions.
Available as an optional add-on to Solid Tumor Profile Plus™, this IHC panel adds biomarker-specific protein expression analysis for PD-L1, FOLR1, CLDN18, and MET. It is designed to complement genomic and transcriptomic profiling with additional actionable information that can support therapy selection and personalized treatment planning.
The IHC Add-On for Solid Tumor Profile Plus™ provides immunohistochemical assessment of PD-L1, FOLR1, CLDN18, and MET in conjunction with comprehensive DNA and RNA profiling. This integrated approach supports correlation of protein expression with underlying genomic and transcriptomic findings, allowing a more complete characterization of tumor biology. In appropriate clinical contexts, these biomarkers may contribute additional information relevant to therapeutic stratification, including consideration of immunotherapy and targeted treatment options.
The test covers >400 DNA genes and >1600 RNA genes.
Sensitivity is 3% for non-hotspot and 1% for hotspots. It is at 0.001 for cases with prior Hx.PD-L1 – can identify patients who would be candidates for pembrolizumab (Keytruda™), nivolumab (Opdivo), atezolizumab (Tencentriq) and other immunotherapies
FOLR1 – can identify patients who would be candidates for mirvetuximab soravtansine (Elahere™)
CLDN.18 – can identify patients who would be candidates for zolbetuximab (Vyloy™)
MET IHC can identify patients with non-small cell lung cancer (NSCLC) who may be eligible for the targeted therapy telisotuzumab vedotin-tllv (EMRELIS™)
Real-world applications of our genomic testing
We provide a selection of real-world case studies that demonstrate the clinical utility and diagnostic impact of our genomic tests. Click the button below to explore individual cases and see how Solid Tumor Profile Plus™ contributes to precision oncology in practice.
Our case study list is continuously updated as new clinical examples become available. We encourage you to revisit this page regularly to explore the latest insights and applications of our genomic testing in real-world settings.
